COSTEM 2019 | Are hypomethylating agents useful in preventing relapse in AML and MDS?

Marcos de Lima

Marcos de Lima, MD, University Hospitals Cleveland Medical Center, Cleveland, OH, discusses hypomethylating agents and their utility in preventing relapse in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

Share this video  
Similar topics